Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protara Therapeutics, Inc. filings document a Nasdaq-listed, Delaware clinical-stage biotechnology company developing TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride for patients receiving parenteral support. Form 8-K disclosures include clinical-data updates, Regulation FD materials, financial results, investor presentations, and business updates related to the company's investigational programs.
The filing record also covers Protara's capital structure and governance, including common stock registered on The Nasdaq Global Market, public offering and underwriting agreements, warrant-related disclosures, and proxy materials for annual stockholder voting. Proxy filings describe board elections, executive compensation matters, equity plans, audit oversight, and other corporate-governance proposals.
Protara Therapeutics, Inc. CEO Jesse Shefferman reported multiple equity transactions in Protara common stock. On June 29, 2026, he exercised stock options to acquire 215,687 shares at an exercise price of $1.91 per share and sold 215,687 shares in open-market transactions at a weighted average price of $4.09 per share, with individual sale prices ranging from $4.03 to $4.14.
On June 30, 2026, Shefferman made bona fide gift transfers totaling 30,000 shares of common stock in four separate transactions. Following these transactions, he holds 691,832 shares directly and 300,000 shares indirectly through The Samhold Family Trust, and 141,313 stock options with a $1.91 exercise price expiring on January 18, 2034.
Protara Therapeutics, Inc. reported that its Chief Medical Officer, Leonardo Viana Nicacio, M.D., has resigned from the company to explore other opportunities, effective June 26, 2026. His responsibilities will transition to Carla Beckham, M.D., the company’s Lead Medical Director and Head of Clinical Development, under the continued oversight of Jacqueline Zummo, Ph.D., Chief Research & Development Officer. This represents a leadership change in the company’s medical and clinical development organization.
Protara Therapeutics director Richard S. Levy received a stock option grant covering 31,000 shares of common stock. The option has an exercise price of $3.94 per share and was granted as a derivative security.
According to the terms, the 31,000 options are scheduled to vest in full on the first anniversary of the grant date, provided Dr. Levy continues to serve on the board through that date. The options will also vest in full upon a Change of Control. Following this grant, his reported derivative holdings from this award total 31,000 options.
Protara Therapeutics director Michael Edward Solomon received a stock option grant for 31,000 shares of Common Stock. The option has an exercise price of $3.94 per share and was granted as a Stock Option (Right to Buy). It vests in full on the first anniversary of the grant date, subject to his continued service on the Board, and will also vest in full upon a Change of Control. Following this award, he holds 31,000 option shares related to this grant, which expires on June 14, 2036.
Protara Therapeutics director Cynthia Smith received a grant of stock options as equity compensation. She was awarded options covering 31,000 shares of common stock at an exercise price of $3.94 per share. These options vest in full on the first anniversary of the grant date, provided she continues to serve on the board, and will also fully vest upon a Change of Control.
Protara Therapeutics director Gregory Sargen received a grant of stock options covering 31,000 shares of common stock. The options have an exercise price of $3.94 per share, expire on June 14, 2036, and will vest in full on the first anniversary of the June 15, 2026 grant date, or upon a Change of Control, subject to his continued Board service. Following this award, the filing shows 31,000 derivative securities held directly.
Protara Therapeutics director Jane Huang received a stock option grant for 31,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 14, 2036. The entire Annual Grant vests on the first anniversary of the June 15, 2026 grant date, subject to her continued board service, and also fully vests upon a Change of Control.
Protara Therapeutics director Roger Garceau received a grant of stock options for 31,000 shares of Common Stock. The options have an exercise price of $3.94 per share, expire on June 14, 2036, and vest in full on the first anniversary of the June 15, 2026 grant date or upon a Change of Control, subject to continued board service.
Protara Therapeutics director Barry P. Flannelly received a grant of stock options covering 31,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 14, 2036.
According to the grant terms, the 31,000 options vest in full on the first anniversary of the June 15, 2026 grant date, as long as the director continues serving on the board, and they vest in full upon a Change of Control.